1-(6-己基吡啶-2-基)哌嗪 | 120144-99-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(6-己基吡啶-2-基)哌嗪
• 英文名称: 1-(6-hexyl-2-pyridinyl)piperazine
• 英文别名: Piperazine, 1-(6-hexyl-2-pyridinyl)-；1-(6-hexylpyridin-2-yl)piperazine
• CAS: 120144-99-2
• 化学式: C₁₅H₂₅N₃
• 分子量: 247.384
• InChiKey: JHZPBMMAYNSZEG-UHFFFAOYSA-N

物化性质

• 沸点：
  124-126 °C(Press: 0.1 Torr)
• 密度：
  0.990±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  仲辛酮 在 sodium 作用下， 以 乙醚 、 正丁醇 为溶剂， 反应 48.0h， 生成 1-(6-己基吡啶-2-基)哌嗪
  参考文献：
  名称：

  6-Alkyl-N,N-disubstituted-2-pyridinamines as anticonvulsant agents

  摘要：

  The anticonvulsant effect of a series of 6-alkyl-N,N-disubstituted-2-pyridinamines is described. An investigation was carried out to optimize the anticonvulsant activity and reduce behavioral side effects in this series. Three compounds (7, 8, 10; Table I) were selected from initial screening for a more complete pharmacological evaluation. While each of these compounds was a potent anticonvulsant agent with ED50 values from 5 to 10 mg/kg, the activity was accompanied by significant behavioral side effects including decreased spontaneous locomotion, ataxia, and ptosis.

  DOI：

  10.1021/jm00126a015

文献信息

• PAVIA, MICHAEL R.;TAYLOR, CHARLES P.;LOBBESTAEL, SANDRA J., J. MED. CHEM., 32,(1989) N, C. 1237-1242
  作者：PAVIA, MICHAEL R.、TAYLOR, CHARLES P.、LOBBESTAEL, SANDRA J.

  DOI：——

  日期：——
• 6-Alkyl-N,N-disubstituted-2-pyridinamines as anticonvulsant agents
  作者：Michael R. Pavia、Charles P. Taylor、Sandra J. Lobbestael

  DOI：10.1021/jm00126a015

  日期：1989.6

  The anticonvulsant effect of a series of 6-alkyl-N,N-disubstituted-2-pyridinamines is described. An investigation was carried out to optimize the anticonvulsant activity and reduce behavioral side effects in this series. Three compounds (7, 8, 10; Table I) were selected from initial screening for a more complete pharmacological evaluation. While each of these compounds was a potent anticonvulsant agent with ED50 values from 5 to 10 mg/kg, the activity was accompanied by significant behavioral side effects including decreased spontaneous locomotion, ataxia, and ptosis.